文献速递姑息放疗与转移瘤

立体定向体部放疗治疗寡转移患者队列中反应与生存的预测因素

Predictive Factors for Response and Survival in a Cohort of Oligometastatic Patients Treated With Stereotactic Body Radiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-01-08

本研究纳入2014至2015年接受立体定向体部放疗(SBRT)的358例寡转移患者,评估可预测放疗反应与生存的患者、治疗或疾病特征。中位随访31.83个月,6个月和24个月局部控制率分别为94.6%和78.9%,中位总生存(OS)为34.7个月(95%CI 29.66-43.83)。多变量分析显示肺转移和淋巴结转移与较长OS相关,原发肺癌、年龄增长和非照射部位转移是较短OS的独立预测因素,局部反应与OS相关。

要点

  • 358例寡转移患者接受SBRT,中位随访31.83个月,中位OS为34.7个月(95%CI 29.66-43.83)。
  • 6个月和24个月局部控制率分别为94.6%和78.9%,远处进展见于279例(77.9%)。
  • 肺转移(HR 0.50)和淋巴结转移(HR 0.44)与较长OS相关,原发肺癌(HR 1.89)、年龄增长(HR 1.02)和非照射部位转移(HR 2.19)与较短OS独立相关。

核心结论

  • SBRT对寡转移疾病患者有效,局部反应与患者预后强烈相关,并突显其在转移背景下的意义。

研究设计与样本

  • 研究纳入2014年至2015年间接受SBRT的寡转移疾病患者,寡转移定义为最多5个活动病灶位于3个不同部位,且须接受根治性意图的SBRT,共纳入358例患者。

主要发现

  • 中位随访31.83个月,6个月和24个月局部控制率分别为94.6%和78.9%。
  • 279例(77.9%)记录到远处进展,6个月和24个月无进展生存率分别为66.1%和18.4%。
  • 末次随访时195例(54.5%)仍存活,其中59例无疾病证据。
  • 中位总生存(OS)为34.7个月(95%置信区间29.66-43.83),6个月和24个月OS分别为96.07%和63.57%。
  • 多变量分析中,肺转移(风险比[HR] 0.50 [0.33-0.75];P=0.001)和淋巴结转移(HR 0.44 [0.24-0.78];P=0.005)与较长OS相关;原发肺癌(HR 1.89 [1.14-3.13];P=0.013)、年龄增长(HR 1.02 [1.01-1.04];P=0.002)和非照射部位转移(HR 2.19 [1.39-3.43];P=0.001)均为较短OS的独立预测因素。

关键数值与推荐

  • 寡转移定义:最多5个活动病灶位于3个不同部位。
  • 肺转移与较长OS相关:HR 0.50(95%CI 0.33-0.75),P=0.001。
  • 淋巴结转移与较长OS相关:HR 0.44(95%CI 0.24-0.78),P=0.005。
  • 原发肺癌与较短OS相关:HR 1.89(95%CI 1.14-3.13),P=0.013。
  • 年龄增长与较短OS相关:HR 1.02(95%CI 1.01-1.04),P=0.002;非照射部位转移与较短OS相关:HR 2.19(95%CI 1.39-3.43),P=0.001。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study evaluated patients, treatment, or disease characteristics that could predict response to stereotactic body radiation therapy (SBRT) and survival in a database of patients with oligometastatic disease from different solid tumors. METHODS AND MATERIALS: Patients treated with SBRT for oligometastatic disease between 2014 and 2015 were included. Patients were defined as oligometastatic if they were affected by a maximum of 5 active lesions in 3 different sites. They had to be treated with SBRT with radical intent. RESULTS: The study included 358 patients. With a median follow-up of 31.83 months, local control at 6 and 24 months was 94.6% and 78.9%, respectively. Distant progression was recorded in 279 patients (77.9%). Progression-free survival at 6 and 24 months was 66.1% and 18.4%, respectively. At last follow-up, 195 patients (54.5%) were still alive in 59 cases with no evidence of disease. The median overall survival (OS) was 34.7 months (95% confidence interval, 29.66-43.83). OS at 6 and 24 months was 96.07% and 63.57%, respectively. On multivariable analysis, the presence of lung metastases (hazard ratio [HR], 0.50 [0.33-0.75]; P = .001) and nodal metastases (HR, 0.44 [0.24-0.78]; P = .005) was related to longer OS. Primary lung cancer (HR, 1.89 [1.14-3.13]; P = .013), increasing age (HR, 1.02 [1.01-1.04]; P = .002), and the presence of metastatic sites other than the irradiated ones (HR, 2.19 [1.39-3.43]; P = .001) were all independent predictors of shorter OS. Local response was associated with OS. CONCLUSIONS: SBRT for patients with oligometastatic disease is effective. Local response is strongly correlated with patients'' prognosis, also underlying its relevance in a metastatic setting.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Franceschini D, De Rose F, Franzese C, et al. Predictive Factors for Response and Survival in a Cohort of Oligometastatic Patients Treated With Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2019. PMID: 30630030. doi:10.1016/j.ijrobp.2018.12.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。